Mpox and HIV: A Practical Guide for New Yorkers Who Cannot Afford to Wait for Clarity

When mpox first surged through New York City in the summer of 2022, the public health response was, by many accounts, too slow and too uneven. Communities already burdened by HIV — particularly gay and bisexual men of color — bore a disproportionate share of cases while waiting for vaccine access that took weeks to materialize. The lessons of that outbreak are still being absorbed. And with mpox remaining an active concern globally and domestically, HIV-positive New Yorkers deserve clear, direct information tailored to their specific circumstances.

This is that information.

Why HIV Status Changes the Mpox Calculus

For most people with healthy immune systems, mpox is a painful but self-limiting illness. The rash, the lesions, the flu-like symptoms — they are serious, but the body typically clears the infection within two to four weeks without specialized treatment.

For people living with HIV — particularly those whose CD4 counts fall below 200 cells per cubic millimeter, or who are not yet virally suppressed — the picture can be considerably more complicated. Research published during and after the 2022 outbreak documented that immunocompromised individuals faced higher rates of severe mpox disease, including more extensive and persistent lesions, involvement of mucous membranes, and in some cases, life-threatening complications.

This is not a reason for panic. It is a reason for preparedness.

"The message I want people to hear is not 'be afraid,'" said one infectious disease physician at a New York City community health center who works extensively with HIV-positive patients. "The message is: know your immune status, know your options, and don't wait until you're sick to figure out what resources exist."

Understanding Transmission: What's Real and What's Not

Mpox spreads primarily through direct, prolonged skin-to-skin contact with an infected person's rash, lesions, or bodily fluids. It can also spread through contact with contaminated materials — bedding, clothing, towels — and, to a lesser degree, through respiratory droplets during extended face-to-face interaction.

It is not transmitted through casual contact in the way that respiratory viruses are. You cannot contract mpox by walking past someone on the subway or sharing an elevator. Understanding this distinction matters because misinformation about mpox transmission has fueled stigma — including within LGBTQ+ communities — that discourages people from seeking testing and care.

HIV does not make a person more likely to contract mpox through a given exposure. What HIV-related immune suppression does affect is how the body responds once infection occurs. The distinction is important: the virus enters through the same routes regardless of immune status, but the clinical course can diverge significantly.

Recognizing Symptoms — Including the Atypical Ones

Classic mpox presentation includes a rash that progresses through defined stages — from flat spots to raised bumps to fluid-filled blisters to scabs — often preceded by fever, swollen lymph nodes, muscle aches, and fatigue. In the 2022 outbreak, however, many cases presented atypically: lesions appearing in the genital or anal region without a widespread rash, or appearing without significant systemic symptoms.

For HIV-positive individuals, especially those with lower CD4 counts, lesions may be more numerous, more severe, and slower to heal. In some documented cases, lesions persisted for months. If you develop any unexplained skin lesions — regardless of their location or whether they match a textbook description — contact your healthcare provider promptly and mention your HIV status.

Do not wait for a "classic" presentation. Atypical does not mean less serious.

Vaccination: Who Qualifies, Where to Go in NYC

The JYNNEOS vaccine — a two-dose series administered four weeks apart — is the primary mpox vaccine available in the United States and is considered safe for immunocompromised individuals, including people living with HIV. Unlike older smallpox vaccines, JYNNEOS uses a non-replicating virus and does not carry the risks associated with live vaccines in immunocompromised hosts.

In New York City, vaccination is available through several channels:

• NYC Health + Hospitals facilities offer mpox vaccination. Appointments can be scheduled at nyc.gov/health.
• Community health centers across the five boroughs, including those affiliated with Callen-Lorde Community Health Center and Housing Works, provide vaccination as part of sexual health and HIV care services.
• The NYC Sexual Health Clinics network offers walk-in and appointment-based vaccination.

HIV-positive individuals — particularly those with CD4 counts below 200 or with a history of AIDS-defining conditions — should discuss vaccination timing with their HIV provider. While JYNNEOS is safe for immunocompromised individuals, the immune response may be less robust in those with significant immune suppression, making the conversation about optimal timing worthwhile.

If you are uninsured or underinsured, vaccination is available at no cost through public health channels. Do not allow cost to be a barrier.

Treatment Options When Prevention Isn't Enough

Tecovirimat (TPOXX) is the primary antiviral used to treat mpox in the United States. During the 2022 outbreak, it was available primarily through an expanded access protocol, which created significant bureaucratic delays. Access has since been streamlined, though it remains a prescription medication requiring clinical evaluation.

For HIV-positive individuals with severe or prolonged mpox disease, tecovirimat treatment is strongly recommended. If you are diagnosed with mpox and are HIV-positive, explicitly inform your treating provider of your CD4 count and viral load status — this information should directly inform their treatment approach.

Additional supportive treatments, including wound care for extensive lesions and pain management, are also part of the clinical picture for severe cases.

Community Voices: What People Are Actually Navigating

David, a 38-year-old HIV-positive man in the Bronx who contracted mpox in 2022, described his experience navigating the healthcare system while immunocompromised as "exhausting in a way that went beyond the physical symptoms."

"I had to explain my HIV status at every step, advocate for TPOXX when the first clinic I went to wasn't sure how to access it, and do all of that while feeling genuinely terrible," he said. "What I needed was someone who already knew all of this and could walk me through it. That's what community organizations can do that a busy emergency room cannot."

His advice to other HIV-positive New Yorkers: establish a relationship with a provider who understands both HIV and mpox before you need urgent care. Know your most recent CD4 count. Have the phone numbers for Callen-Lorde, Housing Works, or your nearest community health center saved in your phone.

The Bottom Line for HIV-Positive New Yorkers

Mpox is not a crisis that demands fear. It is a condition that demands preparation. For people living with HIV, that preparation looks like knowing your immune status, getting vaccinated if you haven't already, recognizing atypical symptoms, and understanding that treatment exists and is accessible.

New York City has the infrastructure, the community organizations, and the medical expertise to support you. The gap is often information — and that gap is closeable.

For vaccination locations, testing resources, and connections to HIV-competent care, visit aidsnyc.org or contact the NYC Health Department's Sexual Health Clinic network at 347-396-7959.

You deserve care that accounts for the full complexity of your health. Don't navigate this alone.